Influence of rosuvastatin on inflammatory factors and immune function in chronic obstructive pulmonary disease with pulmonary heart disease
10.3760/cma.j.issn.1008-6706.2017.06.016
- VernacularTitle:瑞舒伐他汀对慢性阻塞性肺疾病合并肺心病患者炎性因子及免疫功能的影响
- Author:
Xiaohui JIN
;
Hongyan ZHU
- Keywords:
Rosuvastatin;
Pulmonary heart disease;
Pulmonary disease,chronic obstructive;
Inflam-matory factors;
Immune function
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(6):861-865
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the influence of rosuvastatin on inflammatory factors and immune func-tion in chronic obstructive pulmonary disease(COPD)with pulmonary heart disease.Methods 80 COPD patients with pulmonary heart disease were randomly divided into two groups,40 cases in each group.The control group was treated with conventional medicine comprehensive treatment,the observation group was given rosuvastatin based on the control group.The inflammatory cytokines (TNF -α,IL -1 and hs -CRP)changes,immunoglobulin IgM,IgG and IgA changes situation,and heart,lung function changes related indicators were compared between the two groups before and after the treatment.Results After treatment,the TNF -α,IL -1 and hs CRP levels of the observation group were significantly lower than those before treatment(t =145.5,35.35,57.5,all P <0.05)and those of the control group(t =160.75,11.45,32.99,all P <0.05).After treatment,the IgM,IgG and IgA levels of the observa-tion group were significantly lower than those before treatment (t =4.89 of 18.29,3.42,all P <0.05)and those of the control group (t =2.55 9.67,2.342,all P <0.05 ).After treatment,the FEV1 ,FEV1 /FVC and LVEF of the observation group were significantly higher than those before treatment(t =40.44 33.64,33.79,all P <0.05),while the PAP level was significantly lower than that before treatment (t =24.12,P <0.05),and the FEV1 ,FEV1 /FVC and LVEF of the observation group were significantly higher than those of the control group after treatment(t =16.30, 15.82,18.72,all P <0.05),while the PAP level was significantly lower than that of the control group after treatment (t =13.43,P <0.05).Conclusion Combined rosuvastatin therapy for COPD patients with pulmonary heart disease can effectively reduce body inflammatory response,improve immune function and myocardial contractility,so it can promote functional recovery of heart and lung in patients.
